Novelty in Biomedicine

Jin Y, Yang H, Ji W, et al. Virology, Epidemiology, Pathogenesis, and Control of COVID-19. Viruses. 2020;12(4).

Huang Y-C, Lee P-I and Hsueh P-R. Evolving Reporting Criteria of COVID-19 in Taiwan during the Epidemic. J Microbiol Immunol Infect. 2020;53(3):413–8.

Salzberger B, Buder F, Lampl B, et al. Epidemiology of SARS-CoV-2. Infection. 2021;49(2):233–239.

Gao Z, Xu Y, Sun C, et al. A Systematic Review of Asymptomatic Infections with COVID-19. J Microbiol Immunol Infect. 2021;54(1):12–6.

Cascella M, Rajnik M, Cuomo A, et al. StatPearls Publishing; 2020. Featur Eval Treat coronavirus (COVID-19)[Google Sch n.d.

Padoan A, Sciacovelli L, Basso D, et al. IgA-Ab Response to Spike Glycoprotein of SARS-CoV-2 in Patients with COVID-19: A Longitudinal Study. Clin Chim Acta. 2020;507:164–6.

Lu R, Zhao X, Li J, et al. Genomic Characterisation and Epidemiology of 2019 Novel Coronavirus: Implications for Virus Origins and Receptor Binding. Lancet (London, England). 2020;395(10224):565–74.

Wei M, Yuan J, Liu Y, et al. Novel Coronavirus Infection in Hospitalized Infants Under 1 Year of Age in China. JAMA. 2020;323(13):1313–4.

Wang M, Wu Q, Xu W, et al. Clinical Diagnosis of 8274 Samples with 2019-Novel Coronavirus in Wuhan. MedRxiv. 2020.

Chen H, Guo J, Wang C, et al. Clinical Characteristics and Intrauterine Vertical Transmission Potential of COVID-19 Infection in Nine Pregnant Women: A Retrospective Review of Medical Records. Lancet (London, England). 2020;395(10226):809–15.

Mehta P, McAuley DF, Brown M, et al. COVID-19: Consider Cytokine Storm Syndromes and Immunosuppression. Lancet (London, England). 2020;395(10229):1033–4.

Wu Z and McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 2020;323(13):1239–42.

Conti P and Younes A. Coronavirus COV-19/SARS-CoV-2 Affects Women Less than Men: Clinical Response to Viral Infection. J Biol Regul Homeost Agents. 2020;34(2):339–43.

Gao F, Zheng KI, Wang X-B, et al. Obesity Is a Risk Factor for Greater COVID-19 Severity. Diabetes Care. 2020;43(7): 72–4.

Hoiland RL, Fergusson NA, Mitra AR, et al. The Association of ABO Blood Group with Indices of Disease Severity and Multiorgan Dysfunction in COVID-19. Blood Adv. 2020;4(20):4981–9.

Huang C, Wang Y, Li X, et al. Clinical Features of Patients Infected with 2019 Novel Coronavirus in Wuhan, China. Lancet (London, England). 2020;395(10223):497–506.

Rudnick MR and Hilburg R. Acute Kidney Injury in COVID-19: Another Challenge for Nephrology. Am J Nephrol. 2020;51(10):761–3.

Lazarian G, Quinquenel A, Bellal M, et al. Autoimmune Haemolytic Anaemia Associated with COVID‐19 Infection. Br J Haematol 2020.

Zulfiqar A-A, Lorenzo-Villalba N, Hassler P, et al. Immune Thrombocytopenic Purpura in a Patient with Covid-19. N Engl J Med. 2020;382(18):e43.

Toscano G, Palmerini F, Ravaglia S, et al. Guillain–Barré Syndrome Associated with SARS-CoV-2. N Engl J Med. 2020;382(26):2574–6.

Becker RC. COVID-19-Associated Vasculitis and Vasculopathy. J Thromb Thrombolysis. 2020;50(3):499–511.

Galeotti C and Bayry J. Autoimmune and Inflammatory Diseases Following COVID-19. Nat Rev Rheumatol. 2020;16(8):413–4.

Viner RM and Whittaker E. Kawasaki-like Disease: Emerging Complication during the COVID-19 Pandemic. Lancet. 2020;395(10239):1741–3.

Noris M, Benigni A and Remuzzi G. The Case of Complement Activation in COVID-19 Multiorgan Impact. Kidney Int. 2020;98(2):314–22.

Roncati L, Ligabue G, Fabbiani L, et al. Type 3 Hypersensitivity in COVID-19 Vasculitis. Clin Immunol 2020;217:108487.

Mantovani Cardoso E, Hundal J, Feterman D, et al. Concomitant New Diagnosis of Systemic Lupus Erythematosus and COVID-19 with Possible Antiphospholipid Syndrome. Just a Coincidence? A Case Report and Review of Intertwining Pathophysiology. Clin Rheumatol. 2020;39(9):2811–5.

Zhang Y, Xiao M, Zhang S, et al. Coagulopathy and Antiphospholipid Antibodies in Patients with Covid-19. N Engl J Med. 2020;382(17):e38.

Sa Ribero M, Jouvenet N, Dreux M, et al. Interplay between SARS-CoV-2 and the Type I Interferon Response. PLoS Pathog. 2020;16(7):e1008737.

Peiris JSM, Hui KPY and Yen H-L. Host Response to Influenza Virus: Protection versus Immunopathology. Curr Opin Immuno.l 2010;22(4):475–81.

Cheng H-Y, Jian S-W, Liu D-P, et al. Contact Tracing Assessment of COVID-19 Transmission Dynamics in Taiwan and Risk at Different Exposure Periods Before and After Symptom Onset. JAMA Intern Med. 2020;180(9):1156–63.

Gu J, Gong E, Zhang B, et al. Multiple Organ Infection and the Pathogenesis of SARS. J Exp Med. 2005;202(3):415–24.

Zhou Y, Fu B, Zheng X, et al. Pathogenic T-Cells and Inflammatory Monocytes Incite Inflammatory Storms in Severe COVID-19 Patients. Natl Sci Rev. 2020;7(6):998–1002.

Chen L, Li X, Chen M, et al. The ACE2 Expression in Human Heart Indicates New Potential Mechanism of Heart Injury among Patients Infected with SARS-CoV-2. Cardiovasc Res. 2020;116(6):1097–100.

Channappanavar R, Fehr AR, Zheng J, et al. IFN-I Response Timing Relative to Virus Replication Determines MERS Coronavirus Infection Outcomes. J Clin Invest. 2019;129(9):3625–39.

Karmakar D, Lahiri B, Ranjan P, et al. Road Map to Understanding SARS-CoV-2 Clinico-Immunopathology and COVID-19 Disease Severity. Pathog (Basel, Switzerland). 2020;10(1).

Rajendran K, Krishnasamy N, Rangarajan J, et al. Convalescent Plasma Transfusion for the Treatment of COVID-19: Systematic Review. J Med Virol. 2020;92(9):1475–83.

Poland GA, Ovsyannikova IG and Kennedy RB. SARS-CoV-2 Immunity: Review and Applications to Phase 3 Vaccine Candidates. Lancet (London, England). 2020;396(10262):1595–606.

Thevarajan I, Nguyen THO, Koutsakos M, et al. Breadth of Concomitant Immune Responses Prior to Patient Recovery: A Case Report of Non-Severe COVID-19. Nat Med. 2020;26(4):453–5.

Sekine T, Perez-Potti A, Rivera-Ballesteros O, et al. Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19. Cell. 2020;183(1):158-68.

Cañas CA. The Triggering of Post-COVID-19 Autoimmunity Phenomena Could Be Associated with oth Transient Immunosuppression and an Inappropriate Form of Immune Reconstitution in Susceptible Individuals. Med Hypotheses. 2020;145:110345.

Pedersen SF and Ho Y-C. SARS-CoV-2: A Storm Is Raging. J Clin Invest. 2020;130(5):2202–5.

Rodríguez Y, Novelli L, Rojas M, et al. Autoinflammatory and Autoimmune Conditions at the Crossroad of COVID-19. J Autoimmun 2020;114:102506; doi: 10.1016/j.jaut.2020.102506.

Yang M. Cell Pyroptosis, a Potential Pathogenic Mechanism of 2019-NCoV Infection. SSRN J n.d.

Acharya D, Liu G and Gack MU. Dysregulation of Type I Interferon Responses in COVID-19. Nat Rev Immunol. 2020;20(7):397–8.

Oberfeld B, Achanta A, Carpenter K, et al. SnapShot: COVID-19. Cell. 2020;181(4):954-4.

Sánchez-Cerrillo I, Landete P, Aldave B, et al. Differential Redistribution of Activated Monocyte and Dendritic Cell Subsets to the Lung Associates with Severity of COVID-19. medRxiv. 2020;2020.05.13.20100925.

Odak I, Barros-Martins J, Bošnjak B, et al. Reappearance of Effector T Cells Is Associated with Recovery from COVID-19. EbioMedicine. 2020;57:102885.

Qin C, Zhou L, Hu Z, et al. Dysregulation of Immune Response in Patients With Coronavirus 2019 (COVID-19) in Wuhan, China. Clin Infect Dis an Off Publ Infect Dis Soc Am. 2020;71(15):762–8.

Huang Y, Chen Z, Wang Y, et al. Clinical Characteristics of 17 Patients with COVID-19 and Systemic Autoimmune Diseases: A Retrospective Study. Ann Rheum Dis. 2020;79(9):1163–9.

Serrano NC, Millan P and Páez M-C. Non-HLA Associations with Autoimmune Diseases. Autoimmun Rev. 2006;5(3):209–14.

Teruel M and Alarcón-Riquelme ME. Genetics of Systemic Lupus Erythematosus and Sjögren’s Syndrome: An Update. Curr Opin Rheumatol. 2016;28(5):506–14.

Nusbaum JS, Mirza I, Shum J, et al. Sex Differences in Systemic Lupus Erythematosus: Epidemiology, Clinical Considerations, and Disease Pathogenesis. Mayo Clin Proc. 2020;95(2):384–94.

Moulton VR. Sex Hormones in Acquired Immunity and Autoimmune Disease. Front Immunol 2018;9:2279.

Safadi MAP and Silva CAA da. The challenging and unpredictable spectrum of covid-19 in children and adolecents. rev paul pediatr. 2020;39:e2020192.

Fernández-Sarmiento J, De Souza D, Jabornisky R, et al. Paediatric Inflammatory Multisystem Syndrome Temporally Associated with COVID-19 (PIMS-TS): A Narrative Review and the Viewpoint of the Latin American Society of Pediatric Intensive Care (SLACIP) Sepsis Committee. BMJ Paediatr open. 2021;5(1):e000894.

Alunno A, Carubbi F and Rodríguez-Carrio J. Storm, Typhoon, Cyclone or Hurricane in Patients with COVID-19? Beware of the Same Storm That Has a Different Origin. RMD open. 2020;6(1).

Channappanavar R and Perlman S. Pathogenic Human Coronavirus Infections: Causes and Consequences of Cytokine Storm and Immunopathology. Semin Immunopathol. 2017;39(5):529–39.

Recalcati S, Invernizzi P, Arosio P, et al. New Functions for an Iron Storage Protein: The Role of Ferritin in Immunity and Autoimmunity. J Autoimmun. 2008;30(1–2):84–89.

Castillo L and Carcillo J. Secondary Hemophagocytic Lymphohistiocytosis and Severe Sepsis/ Systemic Inflammatory Response Syndrome/Multiorgan Dysfunction Syndrome/Macrophage Activation Syndrome Share Common Intermediate Phenotypes on a Spectrum of Inflammation. Pediatr Crit care Med a J Soc Crit Care Med World Fed Pediatr Intensive Crit Care Soc. 2009;10(3):387–92.

Mahase E. Covid-19: Concerns Grow over Inflammatory Syndrome Emerging in Children. BMJ .2020;369:m1710.

Belhadjer Z, Méot M, Bajolle F, et al. Acute Heart Failure in Multisystem Inflammatory Syndrome in Children in the Context of Global SARS-CoV-2 Pandemic. Circulation. 2020;142(5):429–36.

Feldstein LR, Rose EB, Horwitz SM, et al. Multisystem Inflammatory Syndrome in U.S. Children and Adolescents. N Engl J Med. 2020;383(4):334–46.

Dufort EM, Koumans EH, Chow EJ, et al. Multisystem Inflammatory Syndrome in Children in New York State. N Engl J Med. 2020;383(4):347–58.

Ehrenfeld M, Tincani A, Andreoli L, et al. Covid-19 and Autoimmunity. Autoimmun Rev. 2020;19(8):102597.

Burns JC. Commentary: Translation of Dr. Tomisaku Kawasaki’s Original Report of Fifty Patients in 1967. Pediatr Infect Dis J. 2002;21(11):993–5.

McCrindle BW, Rowley AH, Newburger JW, et al. Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Scientific Statement for Health Professionals from the American Heart Association. Circulation. 2017;135(17):927–99.

Taddio A, Rossi ED, Monasta L, et al. Describing Kawasaki Shock Syndrome: Results from a Retrospective Study and Literature Review. Clin Rheumatol. 2017;36(1):223–8.

Burnham JP and Kollef MH. Understanding Toxic Shock Syndrome. Intensive Care Med. 2015;41(9):1707–10.

Li Y, Zheng Q, Zou L, et al. Kawasaki Disease Shock Syndrome: Clinical Characteristics and Possible Use of IL-6, IL-10 and IFN-γ as Biomarkers for Early Recognition. Pediatr Rheumatol Online J. 2019;17(1):1.

Halstead SB. Dengue Antibody-Dependent Enhancement: Knowns and Unknowns. Microbiol Spectr. 2014;2(6).

Wang S-F, Tseng S-P, Yen C-H, et al. Antibody-Dependent SARS Coronavirus Infection Is Mediated by Antibodies against Spike Proteins. Biochem Biophys Res Commun. 2014;451(2):208–14.

Whittaker E, Bamford A, Kenny J, et al. Clinical Characteristics of 58 Children With a Pediatric Inflammatory Multisystem Syndrome Temporally Associated With SARS-CoV-2. JAMA 2020;324(3):259–269; doi: 10.1001/jama.2020.10369.

Consiglio CR, Cotugno N, Sardh F, et al. The Immunology of Multisystem Inflammatory Syndrome in Children with COVID-19. Cell 2020;183(4):968-981.e7; doi: https://doi.org/10.1016/j.cell.2020.09.016.

Anft M, Paniskaki K, Blazquez-Navarro A, et al. COVID-19 Progression Is Potentially Driven by T Cell Immunopathogenesis. Medrxiv 2020.

Pierce CA, Preston-Hurlburt P, Dai Y, et al. Immune Responses to SARS-CoV-2 Infection in Hospitalized Pediatric and Adult Patients. Sci Transl Med 2020;12(564).

Shimabukuro-Vornh.agen A, Gödel P, Subklewe M, et al. Cytokine Release Syndrome. J Immunother cancer. 2018;6(1):56.

Ravichandran S, Tang J, Grubbs G, et al. SARS-CoV-2 Immune Repertoire in MIS-C and Pediatric COVID-19. Nat Immunol. 2021;22(11):1452–64.

Onouchi Y, Gunji T, Burns JC, et al. ITPKC Functional Polymorphism Associated with Kawasaki Disease Susceptibility and Formation of Coronary Artery Aneurysms. Nat Genet. 2008;40(1):35–42.

Mateu-Salat M, Urgell E and Chico A. SARS-COV-2 as a Trigger for Autoimmune Disease: Report of Two Cases of Graves’ Disease after COVID-19. J Endocrinol Invest. 2020;43(10):1527–8.

Jensen CE, Wilson S, Thombare A, et al. Cold Agglutinin Syndrome as a Complication of Covid-19 in Two Cases. Clin Infect Pract. 2020;7:100041.

Chan A, Rose J, Alvarez E, et al. Lymphocyte Reconstitution after DMF Discontinuation in Clinical Trial and Real-World Patients with MS. Neurol Clin Pract. 2020;10(6):510–9.

Filosto M, Cotti Piccinelli S, Gazzina S, et al. Guillain-Barré Syndrome and COVID-19: An Observational Multicentre Study from Two Italian Hotspot Regions. J Neurol Neurosurg Psychiatry 2021;92(7):751–756; doi: 10.1136/jnnp-2020-324837.

Guirguis N, Rehman T, Shams Y, et al. SARS-CoV-2 Infection Inducing Immune Thrombocytopenic Purpura: Case Series. Ochsner J. 2021;21(2):187–9.

Pascolini S, Granito A, Muratori L, et al. Coronavirus Disease Associated Immune Thrombocytopenia: Causation or Correlation? J Microbiol Immunol Infect. 2021;54(3):531–3.

Li Z, Li X, Shen J, et al. Miller Fisher Syndrome Associated with COVID-19: An up-to-Date Systematic Review. Environ Sci Pollut Res Int. 2021;28(17):20939–44.

Barzilai O, Ram M and Shoenfeld Y. Viral Infection Can Induce the Production of Autoantibodies. Curr Opin Rheumatol. 2007;19(6):636–43.

Rinaldi M, Perricone C, Ortega-Hernandez O-D, et al. Immune Thrombocytopaenic Purpura: An Autoimmune Cross-Link between Infections and Vaccines. Lupus. 2014;23(6):554–67.

Elalfy MS and Nugent D. Viruses, Anti-Viral Therapy, and Viral Vaccines in Children with Immune Thrombocytopenia. Semin Hematol. 2016;53 Suppl 1:S70-2.

Li C, Li J and Ni H. Crosstalk Between Platelets and Microbial Pathogens. Front Immunol. 2020;11:1962.

Manne BK, Denorme F, Middleton EA, et al. Platelet Gene Expression and Function in Patients with COVID-19. Blood. 2020;136(11):1317–29.

Ellul MA, Benjamin L, Singh B, et al. Neurological Associations of COVID-19. Lancet Neurol. 2020;19(9):767–83.

Bikdeli B, Madhavan M V, Jimenez D, et al. COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up: JACC State-of-the-Art Review. J Am Coll Cardiol. 2020;75(23):2950–73.

Israeli E, Agmon-Levin N, Blank M, et al. Guillain-Barré Syndrome--a Classical Autoimmune Disease Triggered by Infection or Vaccination. Clin Rev Allergy Immunol. 2012;42(2):121–30.

Shoenfeld Y, George J and Peter JB. Guillain-Barré as an Autoimmune Disease. Int Arch Allergy Immunol 1996;109(4):318–326; doi: 10.1159/000237258.

Hughes RAC and Cornblath DR. Guillain-Barre Syndrome. Lancet. 2005;366(9497):1653–66.

Wen W, Su W, Tang H, et al. Immune Cell Profiling of COVID-19 Patients in the Recovery Stage by Single-Cell Sequencing. Cell Discov. 2020;6:31.

Lucchese G and Flöel A. SARS-CoV-2 and Guillain-Barré Syndrome: Molecular Mimicry with Human Heat Shock Proteins as Potential Pathogenic Mechanism. Cell Stress Chaperones. 2020;25(5):731–5.

Ang CW, Jacobs BC and Laman JD. The Guillain-Barré Syndrome: A True Case of Molecular Mimicry. Trends Immunol. 2004;25(2):61–6.

Mori M, Kuwabara S, Fukutake T, et al. Clinical Features and Prognosis of Miller Fisher Syndrome. Neurology. 2001;56(8):1104–6.

Gutiérrez-Ortiz C, Méndez-Guerrero A, Rodrigo-Rey S, et al. Miller Fisher Syndrome and Polyneuritis Cranialis in COVID-19. Neurology. 2020;95(5):e601–e605.

Lantos JE, Strauss SB and Lin E. COVID-19–Associated Miller Fisher Syndrome: MRI Findings. Am J Neuroradiol. 2020;41(7):1184–6.

Huscenot T, Galland J, Ouvrat M, et al. SARS-CoV-2-Associated Cold Agglutinin Disease: A Report of Two Cases. Ann Hematol. 2020;99(8):1943–4.

Schoindre Y, Bollée G, Dumont M-D, et al. Cold Agglutinin Syndrome Associated with a 2009 Influenza A H1N1 Infection. Am J Med 2011;124(2):e1-2; doi: 10.1016/j.amjmed.2010.05.015.

Swiecicki PL, Hegerova LT and Gertz MA. Cold Agglutinin Disease. Blood. 2013;122(7):1114–21.

Lui DTW, Lee CH, Chow WS, et al. Insights from a Prospective Follow-up of Thyroid Function and Autoimmunity among COVID-19 Survivors. Endocrinol Metab (Seoul, Korea) 2021;36(3):582–589; doi: 10.3803/EnM.2021.983.

Chen M, Zhou W and Xu W. Thyroid Function Analysis in 50 Patients with COVID-19: A Retrospective Study. Thyroid 2020;31(1):8–11; doi: 10.1089/thy.2020.0363.

Wei L, Sun S, Xu C, et al. Pathology of the Thyroid in Severe Acute Respiratory Syndrome. Hum Pathol. 2007;38(1):95–102.

Wei W, Yi-xiu YE and Hao YAO. Evaluation and Observation of Serum Thd Parathyroid Hormone in Patients with Severe Acute Respiratory Syndrome. Chinese J Antituberc. 2003;25(4):232.

Wei L, Sun S, Zhang J, et al. Endocrine Cells of the Adenohypophysis in Severe Acute Respiratory Syndrome (SARS). Biochem Cell Biol. 2010;88(4):723–30.

Van den Berghe G. Non-Thyroidal Illness in the ICU: A Syndrome with Different Faces. Thyroid. 2014;24(10):1456–65.

Fliers E, Bianco AC, Langouche L, et al. Thyroid Function in Critically Ill Patients. lancet Diabetes Endocrinol 2015;3(10):816–25.

Tee LY, Harjanto S and Rosario BH. COVID-19 Complicated by Hashimoto’s Thyroiditis. Singapore Med J. 2021;62(5):265.

Oldstone MBA. Molecular Mimicry: Its Evolution from Concept to Mechanism as a Cause of Autoimmune Diseases. Monoclon Antib Immunodiagn Immunother. 2014;33(3):158–65.

Vallianatos CN and Iwase S. Disrupted Intricacy of Histone H3K4 Methylation in Neurodevelopmental Disorders. Epigenomics. 2015;7(3):503–19.

Meppiel E, Peiffer-Smadja N, Maury A, et al. Neurologic Manifestations Associated with COVID-19: A Multicentre Registry. Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis. 2021;27(3):458–46.

Al Maskari N, Al Mukhaini K, Al Abrawi S, et al. SARS-CoV-2-Related Multisystem Inflammatory Syndrome in Children: A Case Series. Sultan Qaboos Univ Med J. 2021;21(2):302–7.

Iba T, Levy JH, Connors JM, et al. The Unique Characteristics of COVID-19 Coagulopathy. Crit Care 2020;24(1):1–8.

Wang Z, Gao X, Miao H, et al. Understanding COVID-19-Associated Coagulopathy: From PIC to SIC or DIC. J Intensive Med. 2021;1(1):35–41.

Wong SH, Lui RN and Sung JJ. Covid-19 and the Digestive System. J Gastroenterol Hepatol. 2020;35(5):744–8.

Klok FA, Kruip M, Van der Meer NJM, et al. Incidence of Thrombotic Complications in Critically Ill ICU Patients with COVID-19. Thromb Res. 2020;191:145–7.

Middeldorp S, Coppens M, van Haaps TF, et al. Incidence of Venous Thromboembolism in Hospitalized Patients with COVID‐19. J Thromb Haemost. 2020;18(8):1995–2002.

Obi AT, Tignanelli CJ, Jacobs BN, et al. Empirical Systemic Anticoagulation Is Associated with Decreased Venous Thromboembolism in Critically Ill Influenza A H1N1 Acute Respiratory Distress Syndrome Patients. J Vasc Surg Venous Lymphat Disord. 2019;7(3):317–24.

Giannis D, Ziogas IA and Gianni P. Coagulation Disorders in Coronavirus Infected Patients: COVID-19, SARS-CoV-1, MERS-CoV and Lessons from the Past. J Clin Virol. 2020;127:104362.

Bao J, Li C, Zhang K, et al. Comparative Analysis of Laboratory Indexes of Severe and Non-Severe Patients Infected with COVID-19. Clin Chim acta. 2020;509:180–194.

George MR. Hemophagocytic Lymphohistiocytosis: Review of Etiologies and Management. J Blood Med. 2014;5:69–86.

Shoenfeld Y. Corona (COVID-19) Time Musings: Our Involvement in COVID-19 Pathogenesis, Diagnosis, Treatment and Vaccine Planning. Autoimmun Rev. 2020;19(6):102538.

Hsueh P-R, Chen P-J, Hsiao C-H, et al. Patient Data, Early SARS Epidemic, Taiwan. Emerg Infect Dis. 2004;10(3):489–93.

McGonagle D, Sharif K, O’Regan A, et al. The Role of Cytokines Including Interleukin-6 in COVID-19 Induced Pneumonia and Macrophage Activation Syndrome-Like Disease. Autoimmun Rev. 2020;19(6):102537.

Seguin A, Galicier L, Boutboul D, et al. Pulmonary Involvement in Patients With Hemophagocytic Lymphohistiocytosis. Chest. 2016;149(5):1294–301.

McGonagle D, O’Donnell JS, Sharif K, et al. Immune Mechanisms of Pulmonary Intravascular Coagulopathy in COVID-19 Pneumonia. Lancet Rheumatol. 2020;2(7): 437–45.

Engelmann B and Massberg S. Thrombosis as an Intravascular Effector of Innate Immunity. Nat Rev Immunol. 2013;13(1):34–45.

Nicolai L, Leunig A, Brambs S, et al. Immunothrombotic Dysregulation in COVID-19 Pneumonia Is Associated with Respiratory Failure and Coagulopathy. Circulation 2020;142(12):1176–89.

Loo J, Spittle DA and Newnham M. COVID-19, Immunothrombosis and Venous Thromboembolism: Biological Mechanisms. Thorax. 2021;76(4):412–20.

Wang J, Jiang M, Chen X, et al. Cytokine Storm and Leukocyte Changes in Mild versus Severe SARS‐CoV‐2 Infection: Review of 3939 COVID‐19 Patients in China and Emerging Pathogenesis and Therapy Concepts. J Leukoc Biol. 2020;108(1):17–41.

Du F, Liu B and Zhang S. COVID-19: The Role of Excessive Cytokine Release and Potential ACE2 down-Regulation in Promoting Hypercoagulable State Associated with Severe Illness. J Thromb Thrombolysis. 2021;51(2):313–329.

Magro C, Mulvey JJ, Berlin D, et al. Complement Associated Microvascular Injury and Thrombosis in the Pathogenesis of Severe COVID-19 Infection: A Report of Five Cases. Transl Res. 2020;220:1–13.

Fletcher-Sandersjöö A and Bellander B-M. Is COVID-19 Associated Thrombosis Caused by Overactivation of the Complement Cascade? A Literature Review. Thromb Res. 2020;194:36–41.

Gillot C, Favresse J, Mullier F, et al. NETosis and the Immune System in COVID-19: Mechanisms and Potential Treatments. Front Pharmacol 2021;12:708302; doi: 10.3389/fphar.2021.708302.

Zuo Y, Yalavarthi S, Shi H, et al. Neutrophil Extracellular Traps (NETs) as Markers of Disease Severity in COVID-19. MedRxiv. Preprint] 2020.

de Bont CM, Boelens WC and Pruijn GJM. NETosis, Complement, and Coagulation: A Triangular Relationship. Cell Mol Immunol 2019;16(1):19–27.

Massberg S, Grahl L, von Bruehl M-L, et al. Reciprocal Coupling of Coagulation and Innate Immunity via Neutrophil Serine Proteases. Nat Med. 2010;16(8):887–96.

Ruf W and Ruggeri ZM. Neutrophils Release Brakes of Coagulation. Nat Med. 2010;16(8):851–2.

Bach J-F. The Effect of Infections on Susceptibility to Autoimmune and Allergic Diseases. N Engl J Med. 2002;347(12):911–20.

Bach J-F. Revisiting the Hygiene Hypothesis in the Context of Autoimmunity. Front Immunol. 2020;11:615192.

Cerf-Bensussan N and Gaboriau-Routhiau V. The Immune System and the Gut Microbiota: Friends or Foes? Nat Rev Immunol. 2010;10(10):735–44.

Quintana-Murci L. Human Immunology through the Lens of Evolutionary Genetics. Cell. 2019;177(1):184–99.

Zeberg H and Pääbo S. The Major Genetic Risk Factor for Severe COVID-19 Is Inherited from Neanderthals. Nature. 2020;587(7835):610–2.

Anonymous. Genomewide Association Study of Severe Covid-19 with Respiratory Failure. N Engl J Med. 2020;383(16):1522–34.

Downes DJ, Cross AR, Hua P, et al. Identification of LZTFL1 as a Candidate Effector Gene at a COVID-19 Risk Locus. Nat Genet. 2021;53(11):1606–15.

Taskent RO, Alioglu ND, Fer E, et al. Variation and Functional Impact of Neanderthal Ancestry in Western Asia. Genome Biol Evol. 2017;9(12):3516–24.

Fernandes R, Viana SD, Nunes S, et al. Diabetic Gut Microbiota Dysbiosis as an Inflammaging and Immunosenescence Condition That Fosters Progression of Retinopathy and Nephropathy. Biochim Biophys acta Mol basis Dis. 2019;1865(7):1876–97.

Geuking MB, Köller Y, Rupp S, et al. The Interplay between the Gut Microbiota and the Immune System. Gut Microbes. 2014;5(3):411–8.

Gu S, Chen Y, Wu Z, et al. Alterations of the Gut Microbiota in Patients With Coronavirus Disease 2019 or H1N1 Influenza. Clin Infect Dis an Off Publ Infect Dis Soc Am. 2020;71(10):2669–78.

Zuo T, Zhang F, Lui GCY, et al. Alterations in Gut Microbiota of Patients With COVID-19 During Time of Hospitalization. Gastroenterology. 2020;159(3):944-55.

Ferreira C, Viana SD and Reis F. Gut Microbiota Dysbiosis-Immune Hyperresponse-Inflammation Triad in Coronavirus Disease 2019 (COVID-19): Impact of Pharmacological and Nutraceutical Approaches. Microorganisms. 2020;8(10).

Lambert DW, Clarke NE and Turner AJ. Not Just Angiotensinases: New Roles for the Angiotensin-Converting Enzymes. Cell Mol Life Sci. 2010;67(1):89–98.

Camargo SMR, Singer D, Makrides V, et al. Tissue-Specific Amino Acid Transporter Partners ACE2 and Collectrin Differentially Interact with Hartnup Mutations. Gastroenterology. 2009;136(3):872–82.

Jando J, Camargo SMR, Herzog B, et al. Expression and Regulation of the Neutral Amino Acid Transporter B0AT1 in Rat Small Intestine. PLoS One. 2017;12(9):e0184845.

Obukhov AG, Stevens BR, Prasad R, et al. SARS-CoV-2 Infections and ACE2: Clinical Outcomes Linked with Increased Morbidity and Mortality in Individuals With Diabetes. Diabetes. 2020;69(9):1875–1886.

Perlot T and Penninger JM. ACE2 - from the Renin-Angiotensin System to Gut Microbiota and Malnutrition. Microbes Infect. 2013;15(13):866–73.

Cheung KS, Hung IFN, Chan PPY, et al. Gastrointestinal Manifestations of SARS-CoV-2 Infection and Virus Load in Fecal Samples From a Hong Kong Cohort: Systematic Review and Meta-Analysis. Gastroenterology. 2020;159(1):81–95.

Zang R, Gomez Castro MF, McCune BT, et al. TMPRSS2 and TMPRSS4 Promote SARS-CoV-2 Infection of Human Small Intestinal Enterocytes. Sci Immunol. 2020;5(47).

Lamers MM, Beumer J, van der Vaart J, et al. SARS-CoV-2 Productively Infects Human Gut Enterocytes. Science. 2020;369(6499):50–4.

Penninger JM, Grant MB and Sung JJY. The Role of Angiotensin Converting Enzyme 2 in Modulating Gut Microbiota, Intestinal Inflammation, and Coronavirus Infection. Gastroenterology. 2021;160(1):39–46.

Gupta A, Karyakarte R, Joshi S, et al. Nasopharyngeal Microbiome Reveals the Prevalence of Opportunistic Pathogens in SARS-CoV-2 Infected Individuals and Their Association with Host Types. Microbes Infect. 2022;24(1):104880.

Zohar T, Loos C, Fischinger S, et al. Compromised Humoral Functional Evolution Tracks with SARS-CoV-2 Mortality. Cell. 2020;183(6):1508-19.

Hassan AO, Case JB, Winkler ES, et al. A SARS-CoV-2 Infection Model in Mice Demonstrates Protection by Neutralizing Antibodies. Cell. 2020;182(3):744-53.

Zhou Y, Han T, Chen J, et al. Clinical and Autoimmune Characteristics of Severe and Critical Cases of COVID-19. Clin Transl Sci. 2020;13(6):1077–86.

Bastard P, Rosen LB, Zhang Q, et al. Autoantibodies against Type I IFNs in Patients with Life-Threatening COVID-19. Science. 2020;370(6515).

Wang EY, Mao T, Klein J, et al. Diverse Functional Autoantibodies in Patients with COVID-19. Nature. 2021;595(7866):283–8.

Wang G, Wu C, Zhang Q, et al. C-Reactive Protein Level May Predict the Risk of COVID-19 Aggravation. In: Open Forum Infectious Diseases Oxford University Press US; 2020; p. ofaa153.

Cheng L, Li H, Li L, et al. Ferritin in the Coronavirus Disease 2019 (COVID‐19): A Systematic Review and Meta‐analysis. J Clin Lab Anal. 2020;34(10):e23618.

Nixon JP, Mavanji V, Butterick TA, et al. Sleep Disorders, Obesity, and Aging: The Role of Orexin. Ageing Res Rev. 2015;20:63–73.